PAA

0.00%

19.5¢ pharmaust limited

PAA 2022 , Human Trials , Covid , MND , Oncology , HVTL-1, K9 Phase III, page-22

First 22 Last

Share
Profile

Follow
Havenots

651 Posts.

486

29/11/21

19:44

Post #: 57944047
Share

Originally posted by kpax: ↑

Hi Havenots,

The Wuhan Virus was a single furin cleavage RNA cell type. Located at the junction S1 and S2. This unique part of the RNA enables cell to cell infusion with our ACE 2.Without a cleavage site the interaction with the human body would be void.

Now to be specific. The Wuhan ( dormant ) variant we tested at WEHI / 360 Laboratory was either of variant A1 / A2 or A3.

To my understanding all tens of thousands of variants found since then have a single cleavage site. Though certain proteins have changed allowing greater affinity with cellular fusion with our ACE 2. Some variants now dormant had more proteins than others. The P1 variant that wreaked havoc in Northern Brazil was one to remember.

By the way the last remnants of the Wuhan Virus was found in Italy in December 2020.

Omicron has been stated to have a double cleavage site making it more transmissible. It was first found on Armistice Day 2021 in Botswana from a HIV/Aids sufferer that was not on retro virals.

Whether this transmits to more serious infection , no one knows yet.

The problem that World has is that if an immunocompromised person who is suffering from Delta gets exposed to Omicron ( which will happen ) the chances of another variant is but a possibility.

The next variant may be a dud. Or it may be transmissible again . Mate, we hope it's a dud. The Spanish flu mutated itself out of existence after a few years.

Finally, Havenots I can't exactly answer your question , but I feel it's in the negative. Again, we don't know until we try . Stay tuned.

We have Bromac and Monepantel in the fire zone for Covid. We have MND as well as a particular human cancer to target . We have a successful completion of a Phase 3 Lymphoma trial to look forward to. All in 2022. For a small Company it's fantastic . There would be Pharmaceutical giants not having a fixture that we have. Enjoy the ride. Enjoy the science if you can, don't dwell on the SP.

Cheers Kpax.

Expand

Hi Kpax,

Thank you for your reply.

Detailed and enlightening as per usual....

Maybe we should be working on MPL’s impact on HIV, and kill two birds with one stone there in SA?

Hopefully we can also get some positive feedback on HTLV-1 in December.

Thanks again.

Havenots

Not long now...

PAA Price at posting: 9.3¢ Sentiment: Buy Disclosure: Held
11 Upvote

1 Great analysis

Reply

Top Stories

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

AVA

Ava Risk Group expands US presence with A$0.7M Substation Deal

LU7

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

RCE

Recce's R327 found effective against E.coli during clinical trial

SVL

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Microcap Wrap: 5 explorers with news out today

LRV

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

SS1

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

CMX

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

There are more pages in this discussion • 1,445 more messages in this thread...

First 22 Last

Add PAA (ASX) to my watchlist

(20min delay)
Last 19.5¢		Change 0.000(0.00%)		Mkt cap ! $86.55M

Open	High	Low	Value	Volume
19.5¢	19.5¢	18.5¢	$330.4K	1.741M

Buyers (Bids)

No.	Vol.	Price($)
1	4071	19.0¢

Sellers (Offers)

Price($)	Vol.	No.
19.5¢	24580	3

View Market Depth

No.	Vol.	Price($)
1	4071	0.190
12	453603	0.185
14	471449	0.180
8	743200	0.175
4	115882	0.170

Price($)	Vol.	No.
0.200	346149	3
0.205	55141	4
0.210	300000	2
0.215	459058	6
0.220	239679	2

Last trade - 16.10pm 28/06/2024 (20 minute delay)

PAA (ASX) Chart

PAA 2022 , Human Trials , Covid , MND , Oncology , HVTL-1, K9 Phase III, page-22

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Ava Risk Group expands US presence with A$0.7M Substation Deal

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Recce's R327 found effective against E.coli during clinical trial

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Microcap Wrap: 5 explorers with news out today

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

PAA 2022 , Human Trials , Covid , MND , Oncology , HVTL-1, K9 Phase III, page-22

Top Stories

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Ava Risk Group expands US presence with A$0.7M Substation Deal

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Recce's R327 found effective against E.coli during clinical trial

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Microcap Wrap: 5 explorers with news out today

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News